ACCORD研究:强化降糖对肾脏微血管结局与死亡率的异质性效应
该研究为ACCORD试验的事后分析,按5年肾衰竭风险(KFRE)将患者分为四分位,评估强化降糖对肾脏微血管结局和全因死亡率的条件性治疗效应。结果显示,基线肾衰竭风险最高的患者从强化降糖中获得的肾脏绝对获益最大,但死亡和低血糖事件的绝对风险也最高。
要点
- KFRE可识别强化降糖肾脏获益更大的患者。
- 高风险患者肾脏获益最大但死亡风险也最高。
- 个体化降糖目标需权衡肾脏获益与死亡风险。
核心结论
- 强化降糖对肾脏微血管结局和全因死亡率的影响随基线肾衰竭风险变化。
- 基线肾衰竭风险最高的患者肾脏绝对获益最大,但死亡绝对风险也最高。
研究设计与样本
- ACCORD试验的事后分析,按5年肾衰竭风险(KFRE)将人群分为四分位。
- 估计各四分位内的条件性治疗效应,并与试验平均治疗效应比较。
主要发现
- 肾脏微血管结局:高风险组7年RMST差异为114.8天(95%CI 58.1至176.4),全试验人群为48.4天(25.3至69.6)。
- 全因死亡率:高风险组7年RMST差异为-56.7天(95%CI -100.2至-17.5),全试验人群为-23.6天(-42.2至-6.6)。
临床怎么用
- 对肾衰竭高风险患者,强化降糖可带来更大的肾脏微血管获益。
- 需同时关注此类患者死亡和低血糖事件的绝对风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Identifying and quantifying treatment effect variation across patients is the fundamental challenge of precision medicine. Here we quantify heterogeneous treatment effects of intensive glycemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, considering three outcomes of interest-a composite kidney outcome (driven by macroalbuminuria), all-cause mortality, and first assisted hypoglycemic event. We demonstrate that the effects of intensive glycemic control vary with risk of kidney failure, as predicted by the kidney failure risk equation (KFRE). Participants at highest risk of kidney failure gain the largest absolute kidney benefit of intensive glycemic control but also experience the largest absolute risk of death and hypoglycemic events. Our findings illustrate the value of identifying clinically meaningful treatment heterogeneity, particularly when treatments have different effects on multiple end points. OBJECTIVE: Clear criteria to individualize glycemic targets in patients with type II diabetes are lacking. In this post hoc analysis of the ACCORD, we evaluate whether the KFRE can identify patients for whom intensive glycemic control confers more benefit in preventing kidney microvascular outcomes. RESEARCH DESIGN AND METHODS: We divided the ACCORD trial population into quartiles on the basis of 5-year kidney failure risk using the KFRE. We estimated conditional treatment effects within each quartile and compared them with the average treatment effect in the trial. The treatment effects of interest were the 7-year restricted mean survival time (RMST) differences between intensive and standard glycemic control arms on ( 1 ) time-to-first development of severely elevated albuminuria or kidney failure and ( 2 ) all-cause mortality. RESULTS: We found evidence that the effect of intensive glycemic control on kidney microvascular outcomes and all-cause mortality varies with baseline risk of kidney failure. Patients with elevated baseline risk of kidney failure derived the most from intensive glycemic control in reducing kidney microvascular outcomes (7-year RMST difference of 114.8 [95% confidence interval 58.1 to 176.4] versus 48.4 [25.3 to 69.6] days in the entire trial population) However, this same patient group also experienced a shorter time to death (7-year RMST difference of -56.7 [-100.2 to -17.5] v. -23.6 [-42.2 to -6.6] days). CONCLUSIONS: We found evidence of heterogenous treatment effects of intensive glycemic control on kidney microvascular outcomes in ACCORD as a function of predicted baseline risk of kidney failure. Patients with higher kidney failure risk experienced the most pronounced reduction in kidney microvascular outcomes but also experienced the highest risk of all-cause mortality.
引用
- Charu V, Liang JW, Chertow GM, et al. Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD. J Am Soc Nephrol. 2023. PMID: 38073026. doi:10.1681/ASN.0000000000000272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。